OBJECTIVE The lack of immediate access to a polarized light microscope is often used as an argument to justify the clinical diagnosis of crystal-related arthritis. The aim of this study was to assess the influence of time since sampling and preservation methods on crystal identification in synovial fluid samples under polarized light microscopy. METHODS Prospective, longitudinal, observational factorial study, analyzing 30 synovial fluids samples 12 with monosodium urate crystals (MSU) and 18 with calcium pyrophosphate (CPP) crystals. On extraction, each fluid sample was divided into four subsamples (120 subsamples in total). Two were stored in each type of tube-heparin or ethylenediaminetetra-acetic acid (EDTA) as preserving agents -, at varying temperatures - room temperature or refrigerated at 4°C (39.2°F). Samples were analyzed the following day (T1), at three days (T2), and at seven days (T3) by simple polarized light microscopy, and the presence of crystals was recorded. RESULTS The identification of crystals in the MSU group was similar between groups, with crystals observed in 11/12 (91.7%) of room temperature samples and in 12/12 (100%) of refrigerated samples at T3. However, the identification of CPP crystals tended to decrease in all conditions, especially when preserved with EDTA and kept at room temperature (12/18 [66.7%] at T3), while less reduction was seen in refrigerated heparin-containing tubes. CONCLUSION Preserving samples with heparin in refrigerated conditions allows a delayed microscopic examination for crystals. Avoiding crystal-proven diagnosis due to the immediate unavailability of a microscope no longer appears justified.OBJECTIVE Reactive arthritis (ReA) is a spondyloarthritis triggered by a bacterial infection. In cases where nonsteroidal anti-inflammatory drugs and conventional synthetic disease-modifying antirheumatic drugs have failed, biologics such as tumor necrosis factor inhibitors (TNFi) have been used. However, limited evidence exists of the efficacy and safety of these drugs in ReA. We report on Icelandic patients with ReA who have been treated with TNFi, their characteristics, outcomes, and safety. METHODS We conducted an observational cohort study using the Icelandic nationwide database of biologic therapy (ICEBIO) supplemented with a retrospective study of electronic health record data. Drug efficacy was assessed using disease activity scores and standardized questionnaires within ICEBIO; safety was assessed using ICEBIO and electronic health record data. RESULTS Thirty-eight patients with ReA were registered in the database. Eight were given TNFi within one year of symptom onset. At six and 18 months, there was a significant reduction in C-reactive protein (CRP), tender and swollen joints, Visual Analog Scale for pain and fatigue, Disease Activity Score 28-joint count CRP (DAS28CRP), Clinical Disease Activity Index (CDAI), and Health Assessment Questionnaire (HAQ) scores. Seventy-one to 90% of patients were considered treatment responders. Two patients were able to stop biologics due to remission. During the 303 patient years (mean 8, range 1-15) biologics were given, six hospital admissions for infections were noted. CONCLUSION TNFi are safe and effective in ReA, but treatment tends to be prolonged. Further clinical trials are urgently needed in ReA.OBJECTIVE To reach a consensus on the instruments to be used in clinical practice to evaluate the effectiveness of biological disease-modifying antirheumatic drugs (bDMARD) treatment in PsA patients in the short-medium term (3-6 months), and to establish the minimum health outcomes for treatment continuation. METHODS A two-round Delphi questionnaire was developed based on both the information gathered in the literature review and four discussion groups. The suitability and feasibility of the proposed sets of instruments were assessed on a 7-point Likert scale. Consensus was established when at least 75% of healthcare professionals (HCPs) reached agreement. To define a minimum health outcome in order to continue treatment a combination of four disease activity states and three health-related quality of life states were defined for three hypothetical patient profiles. HCPs were given a dichotomous choice ("yes/no") in response to whether they would continue treatment in each case. RESULTS 106 HCPs completed the second round. Consensus was reached on the use of 1) Disease Activity in Psoriatic Arthritis (DAPSA) + Psoriatic Arthritis Impact of Disease (PsAID-12) or Minimal Disease Activity (MDA) + PsAID-12 + C-reactive protein, in peripheral PsA; and 2) Ankylosing Spondylitis Disease Activity Score (ASDAS) + PsAID-12, in axial PsA. https://www.selleckchem.com/products/fulzerasib.html Health outcomes considered sufficient to continue treatment were stricter for bDMARDs-naïve patients than for patients who failed several bDMARDs. CONCLUSION To the best of our knowledge, this is the first multi-disciplinary consensus on a set of outcomes for the evaluation of bDMARDs effectiveness in PsA, in routine clinical practice.This review focuses on the role of motor vehicles in the prevention of alcohol-related fatalities in the United States. Since alcohol significantly affects brain function, it is natural to make drivers the prime targets for impaired-driving-prevention programs. However, the prevalence, design, ease of operation, and safety features of motor vehicles, as well as state regulations of their operation, have an important influence on crash occurrences, particularly those involving alcohol. This review begins with a discussion of why the automobile became the central technological device in the alcohol-related fatality problem and then moves on to an overview of motor vehicle safety programs that have impacted impaired driving. The article then presents an extended discussion of the effectiveness of vehicle-based, alcohol-detecting ignition interlock devices (interlocks), which provided the principal specific vehicle-based effort in the 20th century to separate alcohol consumption from driving. The review ends with a commentary on the issues that will arise in managing operator impairment in autonomous (self-driving) vehicles-the probable principal 21st-century effort to reduce impaired driving and eliminate alcohol-related crashes by minimizing the role of the driver. Copyright © 2019 Central Police University.